Company: BIAF
Filing Date: 2025-04-15
Form Type: PRE 14A
Source: 0001641172-25-004857
Chunk: 78

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: PRE 14A
Chunk 78
---
LOGIES, INC.

The Board recommends a vote “FOR” all nominees on Proposal 1 and “FOR” Proposals 2, 3, 4 and 5.

| 1. | Election Of Directors. |

|                 |     | FOR |     | AGAINST |     | ABSTAIN |     |              |     | FOR |     | AGAINST |     | ABSTAIN |
| Maria Zannes    |     | ☐   |     | ☐       |     | ☐       |     | Peter Knight |     | ☐   |     | ☐       |     | ☐       |
| Steven Girgenti |     | ☐   |     | ☐       |     | ☐       |     | Gary Rubin   |     | ☐   |     | ☐       |     | ☐       |
| Robert Anderson |     | ☐   |     | ☐       |     | ☐       |     | Roby Joyce   |     | ☐   |     | ☐       |     | ☐       |
| Jamie Platt     |     | ☐   |     | ☐       |     | ☐       |     |              |     |     |     |         |     |         |

<div align='center'>FOR ☐AGAINST ☐ABSTAIN ☐</div>

| 3. | Proposal to consider and approve an amendment to the Company’s Certificate of Incorporation, as amended, in substantially the form attached to the accompanying proxy statement as Appendix A, at the discretion of our Board of Directors (the “Board”), to effect a reverse stock split with respect to the Company’s issued and outstanding shares of common stock, par value $0.007 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-2 to 1-for-25 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment (the “Reverse Stock Split Proposal”). |

<div align='center'>FOR ☐AGAINST ☐ABSTAIN ☐</div>

| 4. | Proposal                                                                                                                              
 to consider and approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 2,926,166 shares of our Common Stock 
 upon the exercise of our common stock purchase warrants